[Comparison of the antilipemic effect of bezafibrate with that of piperazine-sultosilate (A 585). A crossed double-blind study].
In 20 patients suffering from primary hyperlipoproteinaemia the action of sultosilic acid piperazine salt (A-585) was compared with bezafribrate. In a double-blind cross-over study parameters of the lipoprotein metabolism, as well as of fibrinolysis and of platelet function were examined. Both drugs significantly diminished total cholesterol, triglycerides, beta- and pre-beta cholesterol whilst alpha-cholesterol increased. Moreover, both drugs caused a significant shortening of the euglobulin lysis time and a diminution of platelet adhesiveness. In patients under oral anticoagulants the thrombotest levels were not influenced by A-585, but were depressed by bezafibrate. A slightly elevated gamma-GT normalized during bezafibrate therapy but was not influenced by A-585.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000378:metabolism; D001629:Bezafibrate / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000032:analysis; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D008079:Lipoproteins, VLDL / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D010973:Platelet Adhesiveness / Q000187:drug effects; D014280:Triglycerides / Q000032:analysis; D005723:gamma-Glutamyltransferase / Q000378:metabolism
D008076:Cholesterol, HDL; D008079:Lipoproteins, VLDL; D010879:Piperazines; D014280:Triglycerides; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D001629:Bezafibrate
Vergleich der antilipämischen Wirkung von Bezafibrat mit Piperazin-Sultosilat (A 585). Eine gekreuzte Doppelblindstudie.